Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.
Connie L. Batlevi, MD, PhD, a medical oncologist specializing in lymphoma at Memorial Sloan Kettering Cancer Center, discusses emerging therapies in follicular lymphoma.
Several emerging therapies in the follicular lymphoma pipeline have shown encouraging data, says Batlevi.
Strategies based on modulating immune response have comprised a significant area of research, Batlevi explains. Additionally, the utility of CAR T-cell therapy, antibody-drug conjugates, and bispecific antibodies is also being evaluated.
Future research efforts should focus on identifying an optimal sequencing method for patients with follicular lymphoma, especially as more options are introduced to the armamentarium, Batlevi concludes.